ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
69.05
+0.26 (+0.38%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close68.79
Open68.90
Bid67.85 x 2200
Ask69.80 x 900
Day's Range68.88 - 69.25
52 Week Range51.55 - 69.25
Volume9,331,140
Avg. Volume4,695,525
Market Cap121.136B
Beta1.74
PE Ratio (TTM)132.28
EPS (TTM)0.52
Earnings DateOct 17, 2018
Forward Dividend & Yield1.12 (1.64%)
Ex-Dividend Date2018-10-12
1y Target Est71.81
Trade prices are not sourced from all markets
  • Is Abbott Laboratories Trading at a High Valuation in September?
    Market Realist2 days ago

    Is Abbott Laboratories Trading at a High Valuation in September?

    On September 19, Abbott Laboratories (ABT) was trading at a forward PE multiple of 21.8x, while its trailing-12-month PE multiple was 52.4x. Its forward PE and trailing-12-month PE multiples were 19.2x and 55.7x, respectively, a few months ago in May.

  • Abbott Laboratories’ 379th Consecutive Quarterly Dividend
    Market Realist2 days ago

    Abbott Laboratories’ 379th Consecutive Quarterly Dividend

    On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.

  • Abbott Banks on New Approvals and Buyouts, Competition Rife
    Zacks2 days ago

    Abbott Banks on New Approvals and Buyouts, Competition Rife

    Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.

  • ABT Returns Almost Double the S&P 500’s Year-to-Date Gain
    Market Realist2 days ago

    ABT Returns Almost Double the S&P 500’s Year-to-Date Gain

    As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date). In the same period, the S&P 500 has risen ~8%. Abbott Laboratories has clearly surpassed the market’s returns so far in 2018.

  • Abbott Laboratories Stock Trades at Its 52-Week High in September
    Market Realist2 days ago

    Abbott Laboratories Stock Trades at Its 52-Week High in September

    On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price. The stock has maintained growth momentum over the last year.

  • Analysts Are Overwhelmingly Bullish on Abbott Laboratories
    Market Realist3 days ago

    Analysts Are Overwhelmingly Bullish on Abbott Laboratories

    Abbott Laboratories (ABT) is one of the leading medical technology companies in the world. It offers products across its Medical Devices, Nutrition, Diagnostics, and Established Pharmaceuticals segments, with most of its products having the highest market shares in their respective markets. On July 18, the company released its most recent quarterly results and exceeded analysts’ estimates.

  • Abbott Hosts Conference Call for Third-Quarter Earnings
    PR Newswire4 days ago

    Abbott Hosts Conference Call for Third-Quarter Earnings

    ABBOTT PARK, Ill., Sept. 19, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2018 financial results on Wednesday, Oct. 17, 2018 , before the market opens.  The announcement will ...

  • Medical - Products Stock Outlook: Short-Term Pain Inevitable
    Zacks4 days ago

    Medical - Products Stock Outlook: Short-Term Pain Inevitable

    Medical - Products Stock Outlook: Short-Term Pain Inevitable

  • A Look at Hologic Stock’s Recent Performance
    Market Realist4 days ago

    A Look at Hologic Stock’s Recent Performance

    On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.

  • ABT or PETQ: Which Is the Better Value Stock Right Now?
    Zacks5 days ago

    ABT or PETQ: Which Is the Better Value Stock Right Now?

    ABT vs. PETQ: Which Stock Is the Better Value Option?

  • Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
    Zacks5 days ago

    Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

    Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

  • Non-diabetics are using diabetes technology to track their blood sugar and improve their health
    MarketWatch5 days ago

    Non-diabetics are using diabetes technology to track their blood sugar and improve their health

    About two months ago, grad student Azure Grant began wearing a glucose monitor every day. Diabetics have trouble regulating their glucose levels, and thus must track them closely. Here’s the catch: Grant doesn’t have diabetes.

  • A Look at Boston Scientific’s Valuation Multiples in September
    Market Realist6 days ago

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward PE (price-to-earnings) ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x. Boston Scientific’s forward EV-to-EBITDA multiple is 19.1x, which is higher than the industry average of 16.7x. On September 14, Boston Scientific’s peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Medtronic (MDT) had forward PE multiples of 21.7x, 28.4x, and 18.3x, respectively.

  • Boston Scientific Stock in the Week Ended September 14
    Market Realist6 days ago

    Boston Scientific Stock in the Week Ended September 14

    BSX stock is trading ~53.0% higher than its 52-week low of $24.54 reported on December 6, 2017. Over the last week, BSX stock has risen ~4.5%. BSX stock has risen ~11.6% over the last month. Year-to-date, BSX stock has reported stellar gains of ~52.0%.

  • Abbott Labs Declares Quarterly Dividend
    GuruFocus.com8 days ago

    Abbott Labs Declares Quarterly Dividend

    Abbott Laboratories (ABT) closed higher on the New York Stock Exchange on Sept. 13 after the board of directors declared a cash quarterly dividend of 28 cents. Warning! GuruFocus has detected 7 Warning Sign with ABT. Analysts expect 4% growth in the stock's market value, making Abbott Labs an appealing investment option.

  • Moody's9 days ago

    Abbott Ireland Financing DAC -- Moody's assigns Baa1 to Abbott Lab's proposed Euro notes offering

    Moody's Investors Service ("Moody's") today assigned Baa1 ratings to the senior unsecured notes to be offered by Abbott Ireland Financing DAC, a newly-formed financing subsidiary of Abbott Laboratories ("Abbott"). The outlook of Abbott Laboratories is positive. The rating outlook of Abbott Laboratories is positive.

  • Abbott Declares 379th Consecutive Quarterly Dividend
    PR Newswire10 days ago

    Abbott Declares 379th Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 379 th consecutive quarterly ...

  • Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
    PR Newswire10 days ago

    Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)

    ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- For the sixth consecutive year, Abbott (ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries.

  • JNJ Stock Up 7% in the Past Month: What Drove the Bulls?
    Market Realist10 days ago

    JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

    On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.

  • Reuters10 days ago

    India bans 328 combination drugs in setback for pharma companies

    The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Indian government had in 2016 banned about 350 such drugs, referred to as fixed-dose combinations (FDCs), but the industry mounted various legal challenges that prompted the Supreme Court to call for a review by an advisory board. The president of the Indian Drug Manufacturers' Association, Deepnath Roychowdhury, said the order would have an impact on a market worth an estimated 16 billion rupees ($222 million) a year for such drugs, which are produced by both small and large pharmaceutical companies.

  • How Thermo Fisher Fared in the Second Quarter
    Market Realist10 days ago

    How Thermo Fisher Fared in the Second Quarter

    Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.

  • 5 Growth Stocks to Buy for Reliable Income in Retirement
    InvestorPlace10 days ago

    5 Growth Stocks to Buy for Reliable Income in Retirement

    For this reason, some investors will resort to individual growth stocks. For example, dividend aristocrats, or stocks that have seen at least 25 consecutive years of dividend hikes, could bolster such a portfolio.